COLLEGIUM PHARMACEUTICAL, INC Logo

COLLEGIUM PHARMACEUTICAL, INC

Develops and commercializes abuse-deterrent medications for responsible chronic pain management.

COLL | NDAQ

Overview

Corporate Details

ISIN(s):
US19459J1043
LEI:
Country:
United States of America
Address:
100 TECHNOLOGY CENTER DRIVE, 2072 STOUGHTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Collegium Pharmaceutical, Inc. is a specialty biopharmaceutical company dedicated to developing and commercializing medications for people with serious medical conditions. The company's primary focus is on pain management, offering a portfolio of differentiated products designed to treat chronic pain responsibly. A key aspect of its scientific approach is the development of abuse-deterrent formulations. Collegium is engaged in the full lifecycle of its products, from development to commercialization and distribution in the United States, supporting both patients and healthcare providers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all COLLEGIUM PHARMACEUTICAL, INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for COLLEGIUM PHARMACEUTICAL, INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for COLLEGIUM PHARMACEUTICAL, INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea 183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea 446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden EQL
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America EQ
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America ESPR

Talk to a Data Expert

Have a question? We'll get back to you promptly.